Weld Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Weld Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,998	Closed	-$507K	–	478
2020 Q1	$507K	Buy	+5,998	New	+$517K	0.26%	130
2019 Q1	–	Sell	-10,729	Closed	-$914K	–	656
2018 Q4	$914K	Buy	+10,729	New	+$1.02M	0.21%	157

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Weld Capital Management's BMRN Position: Q2 2020 in Review

Weld Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 5,998 shares — an estimated $507K sold.

Weld Capital Management first reported a position in BMRN in Q4 2018 and held it in 2 quarters. The position peaked at $914K in Q4 2018. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Weld Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Weld Capital Management sold 5,998 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $507K.
Weld Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Weld Capital Management's BioMarin Pharmaceuticals position peaked at $914K in Q4 2018.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.